Project Grant R21CA303392
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$416K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $408,966 to support research investigating the use of pharmacological small molecules to enhance the effectiveness of vesicular stomatitis virus (VSV)-based oncolytic viral therapy for treating advanced melanoma. The project aims to determine if locally inhibiting the PI3K/AKT/mTOR signaling pathway in tumors can create conditions for improved intratumoral spread and cancer cell...
This Project Grant award of $414,482 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an improved oncolytic virus therapy for treating glioblastoma, an aggressive type of brain cancer. The key goals are to enhance the therapeutic efficacy of the Semliki Forest Virus (SFV) through directed evolution and engineering the virus to express a cancer-targeting peptide. The research aims to create a...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop an encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund the development and testing of mesenchymal stem...
This $1,377,000 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) aims to develop a novel oncolytic virus platform called VMG for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 3-year project include: Evaluating the VMG oncolytic virus vector's ability to selectively target and destroy PDAC tumor cells while sparing normal tissues, through expression of enzymes to break...
This $177,058 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to discover and optimize novel anti-mitotic agents for the treatment of metastatic melanoma. The grant aims to develop fused heterocyclic pyrazine (FHP) based tubulin inhibitors that can overcome drug resistance and reduce toxicity associated with current treatments. The research involves three key...
This $420,335 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding the role of lytic viral gene expression in the development and maintenance of oncogenic gammaherpesvirus-associated cancers. The University of Arkansas for Medical Sciences (UAMS) is leading this 2-year research project to test the hypothesis that lytic gene expression is...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic is focused on understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The $635,946 award, with a performance period from July 2024 to June 2029, will support research using an autochthonous mouse melanoma model to investigate how UV radiation-induced interferon-I signaling and tumor inflammatory memory...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Research Manpower (CFDA 93.398) program, supports research to decipher the immune evasion mechanisms of cancers harboring mutations in the IDH1 gene. The $196,029 award, effective April 1, 2025 through March 31, 2028, will fund the University of Massachusetts Medical School's investigation into two key processes that contribute to the immunosuppressive tumor microenvironment in IDH1-mutant cancers: 1) the...
This federal Project Grant award of $154,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) is supporting research at Nova Southeastern University to validate targeting spliceosomal proteins HNRNPH1 and H2 as a novel approach for melanoma-targeted and immunotherapy. The key objectives are to: (1) determine the efficacy of specific spliceosomal inhibitors in in vivo models of human melanoma, (2) investigate the...